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Introduction
Without pregnancy-specific protection, an estimated 45% 
of 32 million pregnancies in malaria-endemic sub-
Saharan Africa are exposed to Plasmodium falciparum 
malaria yearly,1 leading to 900 000 malaria-associated low 
birthweight deliveries2 and associated consequences for 
infant health.3 In these areas, WHO recommends 
intermittent preventive treatment in pregnancy (IPTp) 
with antimalarials. IPTp with sulfadoxine-pyrimeth-
amine, the only antimalarial currently recommended for 
this strategy, is associated with major reductions in 
maternal anaemia, low birthweight, and neonatal 
mortality.4 However, the effectiveness of sulfadoxine-
pyrimethamine IPTp is threatened by resistance to this 
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Summary
Background Resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine threatens the antimalarial 
effectiveness of intermittent preventive treatment during pregnancy (IPTp) in sub-Saharan Africa. We aimed to assess 
the associations between markers of sulfadoxine-pyrimethamine resistance in P falciparum and the effectiveness of 
sulfadoxine-pyrimethamine IPTp for malaria-associated outcomes.
Methods For this systematic review and meta-analysis, we searched databases (from Jan 1, 1990 to March 1, 2018) for 
clinical studies (aggregated data) or surveys (individual participant data) that reported data on low birthweight (primary 
outcome) and malaria by sulfadoxine-pyrimethamine IPTp dose, and for studies that reported on molecular markers of 
sulfadoxine-pyrimethamine resistance. Studies that involved only HIV-infected women or combined interventions 
were excluded. We did a random-effects meta-analysis (clinical studies) or multivariate log-binomial regression 
(surveys) to obtain summarised dose-response data (relative risk reduction [RRR]) and multivariate meta-regression to 
explore the modifying effects of sulfadoxine-pyrimethamine resistance (as indicated by Ala437Gly, Lys540Glu, and 
Ala581Gly substitutions in the dhps gene). This study is registered with PROSPERO, number 42016035540.
Findings Of 1097 records screened, 57 studies were included in the aggregated-data meta-analysis (including 
59 457 births). The RRR for low birthweight declined with increasing prevalence of dhps Lys540Glu (ptrend=0·0060) but 
not Ala437Gly (ptrend=0·35). The RRR was 7% (95% CI 0 to 13) in areas of high resistance to sulfadoxine-pyrimethamine 
(Lys540Glu ≥90% in east and southern Africa; n=11), 21% (14 to 29) in moderate-resistance areas (Ala437Gly ≥90% 
[central and west Africa], or Lys540Glu ≥30% to <90% [east and southern Africa]; n=16), and 27% (21 to 33) in low-
resistance areas (Ala437Gly <90% [central and west Africa], or Lys540Glu <30% [east and southern Africa]; n=30; 
ptrend=0·0054 [univariate], I²=69·5%). The overall RRR in all resistance strata was 21% (17 to 25). In the analysis of 
individual participant data from 13 surveys (42 394 births), sulfadoxine-pyrimethamine IPTp was associated with 
reduced prevalence of low birthweight in areas with a Lys540Glu prevalence of more than 90% and Ala581Gly 
prevalence of less than 10% (RRR 10% [7 to 12]), but not in those with an Ala581Gly prevalence of 10% or higher 
(pooled Ala581Gly prevalence 37% [range 29 to 46]; RRR 0·5% [–16 to 14]; 2326 births).
Interpretation The effectiveness of sulfadoxine-pyrimethamine IPTp is reduced in areas with high resistance to 
sulfadoxine-pyrimethamine among P falciparum parasites, but remains associated with reductions in low birthweight 
even in areas where dhps Lys540Glu prevalence exceeds 90% but where the sextuple-mutant parasite (harbouring the 
additional dhps Ala581Gly mutation) is uncommon. Therapeutic alternatives to sulfadoxine-pyrimethamine IPTp are 
needed in areas where the prevalence of the sextuple-mutant parasite exceeds 37%.
Funding US Centers for Disease Control and Prevention, the Malaria in Pregnancy Consortium (funded through a 
grant from the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine), Worldwide Antimalarial 
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Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Articles
Lancet Infect Dis 2019
Published Online 
March 25, 2019 
http://dx.doi.org/10.1016/
S1473-3099(18)30732-1
See Online/Comment 
http://dx.doi.org/10.1016/ 
S1473-3099(18)30796-5
Department of Clinical 
Sciences, Liverpool School of 
Tropical Medicine, Liverpool, 
UK (A M van Eijk PhD, 
G Koshy PhD, C Khairallah MSc, 
Prof F O ter Kuile PhD); 
Department of Public Health, 
Food Studies and Nutrition, 
Syracuse University, Syracuse, 
NY, USA (D A Larsen PhD); 
Malaria Research and Training 
Centre, Department of 
Epidemiology of Parasitic 
Diseases, Faculty of Medicine, 
Pharmacy, and Dentistry, 
University of Sciences, 
Techniques, and Technologies 
of Bamako, Bamako, Mali 
(K Kayentao PhD); Rollins School 
of Public Health, Emory 
University, Atlanta, GA, USA 
(D E C Slaughter SB); Faculty of 
Infectious and Tropical 
Diseases, London School of 
Hygiene & Tropical Medicine, 
London, UK (C Roper PhD); MRC 
Centre for Outbreak Analysis 
and Modelling, Department of 
Infectious Disease 
Epidemiology, Imperial College 
London, London, UK 
(L C Okell PhD); Malaria Branch, 
US Centers for Diseases Control 
and Prevention, Atlanta, GA, 
USA (M Desai PhD, 
J Gutman MD); Department 
of Medicine, University 
of Melbourne, Melbourne, 
VIC, Australia 
(Prof S J Rogerson PhD); 
Department of Genome 
Sciences, University of 
Washington, Seattle, WA, USA 
(Prof C Hopkins Sibley PhD); 
WorldWide Antimalarial 
Resistance Network, University 
of Oxford, Oxford, UK
Articles
2 www.thelancet.com/infection   Published online March 25, 2019   http://dx.doi.org/10.1016/S1473-3099(18)30732-1
drug combination, particularly in east and southern 
Africa.
In P falciparum, sulfadoxine-pyrimethamine resistance 
results from a series of single nucleotide polymorphisms in 
the parasite’s dihydrofolate reductase (dhfr) and dihydrop-
teroate synthase (dhps) genes. At the ecological level, a high 
prevalence of quintuple-mutant P falciparum parasites, 
defined as those that harbour the five most common 
substitutions (dhfr substitutions Asn51Ile, Cys59Arg, and 
Ser108Asn, and dhps substitutions Ala437Gly and 
Lys540Glu), reduces the efficacy of sulfadoxine-pyri-
methamine as an intermittent preventive treatment against 
malaria in infants and children,5,6 undermines the ability of 
sulfadoxine-pyrimethamine to clear existing P falciparum 
infections in asymptomatic pregnant women,7,8 and shor-
tens the post-treatment prophylactic period following IPTp.7 
Sextuple-mutant P falciparum parasites, which harbour the 
additional dhps Ala581Gly mutation, are associated with 
enhanced sulfadoxine-pyrimethamine resistance in vitro, 
sulfa doxine-pyrimethamine treatment failure in patients 
with acute malaria,9–11 and failure of the drug combination to 
inhibit parasite growth or prevent malaria-associated fetal 
growth restriction in pregnant women.12–15
Despite these effects, there are no guidelines on the 
use of molecular prevalence data to inform the use of 
sulfadoxine-pyrimethamine for IPTp.16 The ecological 
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Research in context
Evidence before this study
We searched the Malaria in Pregnancy Library, PubMed, Web of 
Science, and Scopus for studies (published in English, 
up to March 1, 2018) in sub-Saharan Africa of the ecological 
relationship between molecular markers of 
sulfadoxine-pyrimethamine resistance and the effectiveness of 
sulfadoxine-pyrimethamine intermittent preventive treatment 
in pregnancy (IPTp) for preventing low birthweight, preterm 
birth, maternal malaria infection, and maternal anaemia. The 
following search terms were used: “Malaria AND pregnan* AND 
(intermittent OR IPT) AND Review”. We found one prospective 
multi-country study (done in eight sites), two meta-analyses, 
and one modelling study. In the prospective study, prevalence of 
molecular markers of sulfadoxine-pyrimethamine resistance was 
strongly correlated with clearance of existing infections by the 
drug, and with duration of post-treatment prophylaxis, but 
showed no clear trend with regard to reductions in low 
birthweight, maternal anaemia, or plasmodium infections from 
this treatment. In this study, few areas with a high prevalence of 
the highly resistant sextuple-mutant Plasmodium falciparum 
parasite were investigated. One meta-analysis showed, based on 
three studies, no protective effect of sulfadoxine-pyrimethamine 
IPTp (vs placebo or no intervention) against low birthweight in 
areas with more than 50% dhps Lys540Glu mutation prevalence. 
By contrast, the other meta-analysis (nine studies) showed no 
reduced effectiveness of the treatment in areas with high 
sulfadoxine-pyrimethamine resistance. The modelling study did 
not directly investigate the relationship between the effect of 
sulfadoxine-pyrimethamine resistance and the effectiveness of 
sulfadoxine-pyrimethamine, but suggested that, even 
accounting for resistance, extending sulfadoxine-pyrimethamine 
IPTp to all women attending antenatal clinics would have a 
sizeable and cost-effective impact on maternal and infant health. 
Although this inference was valid in most malaria-endemic 
settings in sub-Saharan Africa, the single exception was highly 
resistant areas where sextuple-mutant parasites are common.
Added value of this study
This is the most comprehensive study of the effect of 
sulfadoxine-pyrimethamine resistance on the effectiveness of 
IPTp, involving 57 studies, 13 surveys, and more than 
100 000 births. The aggregated data meta-analysis indicated 
substantial heterogeneity in effect size between studies, 
which might explain the contradictory findings between the 
two previous smaller reviews and the ongoing controversy 
about the continued use of sulfadoxine-pyrimethamine IPTp in 
areas of high resistance. We report for the first time a clear trend 
towards reduced effectiveness of sulfadoxine-pyrimethamine 
IPTp for low birthweight and P falciparum infection with 
increasing prevalence of molecular sulfadoxine-pyrimethamine 
resistance markers. Sulfadoxine-pyrimethamine was protective 
against low birthweight in areas of high resistance where 
parasites with the dhfr and dhps quintuple-mutant haplotype 
are essentially fixed. However, three observational cohort 
studies published elsewhere showed that these beneficial 
effects were not apparent in individuals infected with the highly 
resistant sextuple-mutant parasites (harbouring the quintuple 
mutant haplotype plus dhps Ala581Gly).
Implications of all the available evidence
Overall, evidence suggests a decline in the effectiveness of 
sulfadoxine-pyrimethamine IPTp for reducing malaria 
infection, anaemia, and low birthweight with increasing 
resistance. Nevertheless, use of sulfadoxine-pyrimethamine 
IPTp remains associated with reduced risks of low birthweight, 
even in areas where sulfadoxine-pyrimethamine fails to clear a 
third of asymptomatic infections in women receiving IPTp. 
These findings support WHO’s recommendation to continue 
using sulfadoxine-pyrimethamine for IPTp in these 
high-resistance areas. However, an important exception is areas 
where sextuple mutant parasites are common (≥37% 
prevalence). In such areas, alternative preventive strategies are 
required now. The substantial heterogeneity between studies, 
even in areas with similar resistance levels, suggests that 
single observational studies of the relationship between 
sulfadoxine-pyrimethamine doses and low birthweight might 
not be informative as tools for making policy decisions. 
A decision tool using just two or three mutational markers 
in the dhps gene could be considered to guide 
sulfadoxine-pyrimethamine IPTp policy.
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relationship between molecular measures of sulfadoxine-
pyrimethamine resistance and the effect of sulfa-
doxine-pyrimethamine IPTp on clinically relevant birth 
outcomes, such as low birthweight, is not clear. Previous 
attempts to define these relationships reached conflicting 
conclusions,17,18 possibly reflecting substantial between-
study heterogeneity in the effect of sulfadoxine-
pyrimethamine treatment on low birthweight.14,18
Using all available data derived from observational 
studies, clinical trials, and national surveys in sub-
Saharan Africa, we did a meta-analysis of the ecological 
relationship between molecular markers of sulfadoxine-
pyrimethamine resistance and the effect of sulfadoxine-
pyrimethamine IPTp on low birthweight. We hypothesised 
that a higher prevalence of sulfadoxine-pyrimethamine 
resistance, as indicated by the prevalence of molecular 
markers of sulfadoxine resistance, would be associated 
with an attenuation of the sulfadoxine-pyrimethamine 
IPTp-associated reduction in low birthweight.
Methods
Search strategy and selection criteria
We did a systematic review and meta-analysis in acc-
ordance with the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses statement 
(appendix, p 41). Two main sources of data regarding 
IPTp effectiveness were used: aggregated data from 
observational studies and clinical trials (henceforth 
See Online for appendix
Figure 1: Study profile
dhps=dihydropteroate synthase. IPTp=intermittent preventive treatment in pregnancy. *561 from Malaria in Pregnancy Library, 440 from PubMed, 518 from Web of 
Science, and 502 from Scopus. †63 Demographic and Health Surveys, 13 Malaria Indicator Surveys, 54 Multiple Indicator Cluster Surveys (UNICEF), and eight AIDS 
indicator surveys. ‡Resistance data were not available for Comoros and São Tomé and Príncipe. §39 surveys with individual-level data available and information on out-
comes, exposures, and potential confounders (276 383 single live births: 46% with measured birthweight available, 54% with perceived birthweight; mean birthweight 
3217 g (SD 699), small birth size 14·1% of 276 383, low birthweight 9·4% of 128 347). ¶Comprising 49 481 births (of which 98·2% were singleton livebirths) before exact 
matching, and 42 394 singleton livebirths (19 429 with measured birthweight not available and 22 965 with measured birthweight available) after exact matching.
2021 records identified through database searching* 
1097 titles and abstracts screened
269 full-text records assessed for eligibility
66 articles or studies with information on one or more outcomes of interest 
(comprising 74 mutually exclusive datapoints) included in the review
57 datapoints from 50 source articles contributed to primary outcome 
(low birthweight)
43 observational cross-sectional studies with exposure data recorded 
at the time of delivery
  4 from trials comparing sulfadoxine-pyrimethamine IPTp against 
placebo or passive case detection
  3 from the sulfadoxine-pyrimethamine IPTp arm of other trials
924 duplicates removed
828 records excluded
365 related to policy implementation or reviews
238 studies on sulfadoxine-pyrimethamine IPTp coverage or qualitative studies
143 on treatment efficacy, drug resistance, pharmacokinetics, or modelling
  34 not in pregnant women
24 in HIV-infected women
  14 on cost-effectiveness
  10 outside Africa
203 records not meeting inclusion criteria excluded
68 overlapped with other studies that were included
49 almost all participants received IPTp (no zero-dose control) 
36 outcome during pregnancy, but not at delivery
36 no information on outcomes in relation to sulfadoxine-pyrimethamine dose
12 studies with insufficient detail on the number of sulfadoxine-pyrimethamine 
doses received
1 small sample size with inclusion of twin deliveries
1 multiple cointerventions in the sulfadoxine-pyrimethamine group
138† surveys identified for period 2000–15
39§ surveys with data on outcome, exposure, 
and confounders screened
13 surveys¶ with areas with ≥80% dhps 
Lys540Glu prevalence or super resistance 
      included in primary analysis after exact
      matching
99 not included
77 no birthweight data
14 not in sub-Subharan Africa
3 no data on insecticide-treated net use
2 no resistance data‡
1 no IPTp data
2 other reasons
26 excluded
25 in areas with <80% dhps Lys540Glu prevalence
  1 with no IPTp policy
Aggregated data (observational studies and trials) Individual participant data (surveys)
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referred to collectively as clinical studies), and individual 
participant data from nationally representative surveys 
(referred to as surveys). Clinical studies were identified by 
two independent reviewers (AMvE and GK) by searching 
trial registries and electronic databases (Malaria in 
Pregnancy Library,19 PubMed, Web of Science, and 
Scopus) for studies published between Jan 1, 1990, and 
March 1, 2018, without language restrictions, in addition 
to scanning reference lists of articles and consulting with 
experts in the field (appendix p 2). The search terms 
“Malaria AND pregnan* AND intermittent AND 
(prevent* OR prophyla* OR chemoprevent* OR 
chemoprophyla* OR IPT*) AND (sulfadoxine OR 
sulphadoxine OR pyrimethamine OR SP)” were used. 
Observational studies were included if they were done in 
sub-Saharan Africa, had information at delivery on the 
number of sulfadoxine-pyrimethamine doses received, 
and data on birthweight, maternal haemoglobin, or plas-
modium infection at delivery. Trials were included if they 
were quasi-randomised or randomised trials done in sub-
Saharan Africa, compared sulfadoxine-pyrimethamine 
IPTp against passive case detection or placebo, and 
otherwise fulfilled the same criteria as for the 
observational studies. Studies or study arms were 
excluded if they involved only HIV-infected women or if 
they combined sulfadoxine-pyrimethamine with other 
antimalarial drugs (such as artemisinin derivatives or 
azithromycin) or with other interventions (such as 
screening for malaria). Final study eligibility was agreed 
on by the reviewers. If no agreement could be reached, a 
third reviewer (FOtK) assessed the study and agreement 
was reached by consensus.
To identify surveys, one reviewer (DAL) searched all 
national-level datasets from surveys done in malaria-
endemic countries in Africa after the year 2000 (when 
WHO introduced the sulfadoxine-pyrimethamine IPTp 
policy) and with datasets publicly available (as described 
in detail elsewhere;4 search date May 31, 2015), including 
the Demographic and Health Surveys Program, UNICEF 
Multiple Indicator Cluster Surveys, and Malaria 
Indicator Surveys. Surveys were included if they 
contained data on low birthweight (perceived birth size 
and measured weight), measured IPTp use by number 
of doses among recently pregnant women, and measured 
insecticide-treated net coverage at the household level 
(appendix pp 2–3).
Data on molecular markers of sulfadoxine-pyrimeth-
amine resistance were obtained from the clinical study 
reports or from the authors of those reports. If these data 
were not available, data were obtained from existing 
population prevalence maps of P falciparum dhps mutations 
by use of the molecular surveyor tool of the Worldwide 
Antimalarial Resistance Network (WWARN) and existing 
prediction surfaces of the prevalence of sulfadoxine-
pyrimethamine resistance-associated mutations based on 
these data.16,20–22 Malaria transmission intensity data were 
obtained from the Malaria Atlas Project.
Extraction and quality assessment of IPTp 
effectiveness data
From clinical studies, extraction of summary data was 
done independently by two investigators (AMvE and GK or 
DECS). Authors of primary studies were contacted for 
missing information or if reported data did not fit the 
required format. The following information was extracted: 
first author, publication year, year of study start and end, 
study design, study and randomisation procedures (trials 
only), inclusion criteria (eg, any restrictions by gravidity), 
insecticide-treated net use, numerator and denominator 
per outcome per sulfa doxine-pyrimethamine dose, and 
details of control intervention (trials only). If available, 
sulfadoxine-pyrimethamine resistance data were extracted. 
Study quality was assessed by two reviewers (AMvE and 
GK or DECS) using an adaptation of the Newcastle-Ottawa 
Scale (appendix, p 3).23
From surveys, the following (individual patient-level) data 
were extracted: reported number of sulfadoxine-
pyrimethamine doses received; composite of low birth-
weight (<2·5 kg) if measured birthweight was available, or 
perceived small birth size (very small or small) if 
birthweight was not available (the correlation between 
perceived and measured low birthweight has been 
described elsewhere4); and measured birthweight as a 
continuous variable.4 Other data extracted included number 
of antenatal visits, tetanus vaccination, iron supple-
mentation and insecticide-treated net ownership, house-
hold socio economic status, mother’s education, mother’s 
age and parity, birth spacing, newborn sex, season of birth, 
and whether it was a single or multiple birth.
Data on the prevalence of dhps Ala437Gly, Lys540Glu, 
and Ala581Gly mutations among P falciparum parasites 
were extracted from the clinical studies in pregnant 
women, the literature, and existing molecular surveyor 
databases (appendix p 4).16,20–22 In areas where the 
Figure 2: Relative risk of low birthweight associated with each incremental 
dose of sulfadoxine-pyrimethamine IPTp in all gravidae by resistance strata
On the basis of the estimated prevalence of dhps mutations in the study areas 
(matched as described in text and appendix p 9), resistance was stratified into low 
(Ala437Gly <90% [central and west Africa], or Lys540Glu <30% [east and 
southern Africa]; 30 studies), moderate (Ala437Gly ≥90% [central and west 
Africa], or Lys540Glu ≥30% to <90% [east and southern Africa]; 16 studies), 
and high (Lys540Glu ≥90% in east and southern Africa; 11 studies). p values 
following the I² statistics represent the χ² test for heterogeneity. Weights are from 
random effects analysis. Data marker sizes indicate the weight applied to each 
study using random-effects meta-analysis. Diamonds represent summary effect 
of studies. CW=central and west Africa. dhps=dihydropteroate synthase. 
D+L=Dersimonian-Laird method for random effects models. ES=east and 
southern Africa. IPTp=intermittent preventive treatment in pregnancy. 
I-V=inverse variance method for fixed effects models. *Reference refers to the 
lowest sulfadoxine-pyrimethamine dose category (0 or 0–1 dose as indicated in 
the sulfadoxine-pyrimethamine dose category column), and the comparison 
column (included for illustration only) refers to all the other exposure groups 
pooled (eg, if the sulfadoxine-pyrimethamine categories were 0, 1, 2+, the 
comparison column would reflect the data in the 1 dose group and 2+ dose groups 
pooled; full sample sizes per dose group and average doses are shown in the 
appendix (p 13). †The high prevalence of dhps Ala581Gly in these studies was not 
accompanied by a high prevalence in dhps Lys540Glu, so this information was not 
interpreted as an indication of the presence of sextuple-mutant parasites.
For the Demographic and 
Health Surveys Program see 
http://dhsprogram.com/
For the UNICEF Multiple 
Indicator Cluster Surveys see 
http://mics.unicef.org/
For the Malaria Indicator 
Surveys see http://www.
malariasurveys.org/
For the Malaria Atlas Project 
see http://www.map.ox.ac.uk/
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High-resistance areas
Moderate-resistance areas
Low-resistance areas
I–V overall 0·88 (0·86 to 0·90)
I–V subtotal 0·95 (0·90 to 1·00)
I–V subtotal 0·81 (0·78 to 0·84)
I–V subtotal 0·90 (0·87 to 0·93)
Olliaro et al, 2008, Senegal Mlomp CW 2000–07 0,1,2+ 57/532 (10·7) 29/372 (7·8) 39·3 0·0 0·82 (0·65 to 1·04) 18 (–4 to 35)
Menendez et al, 2008, Mozambique Manhica ES 2003–05 0,2+ 49/411 (11·9) 41/382 (10·7) 62·9 0·0 0·95 (0·78 to 1·15) 5 (–15 to 22)
Yussuf et al, 2010, Tanzania Lindi ES 2009–10 0,1,2+ 55/123 (44·7) 44/123 (35·8) 79·7 0·0 0·85 (0·70 to 1·02) 15 (–2 to 30)
Minja et al, 2013, Tanzania Korogwe ES 2008–10 0–1,2+ 4/17 (23·5) 43/705 (6·1) 100·0 42·9 0·52 (0·33 to 0·80) 48 (20 to 67)
Namusoke et al, 2010, Uganda Kampala ES 2004–05 0,1,2+ 28/162 (17·3) 19/159 (11·9) 93·5 0·0 0·74 (0·49 to 1·12) 26 (–12 to 51)
Bouyou-Akotet et al, 2010, Gabon Libreville CW 2005–06 0,1+ 24/120 (20·0) 11/83 (13·3) 69·0 0·0 0·77 (0·51 to 1·17) 23 (–17 to 49)
Challis et al, 2004, Mozambique Maputo ES 2001–02 0,2+ 27/203 (13·3) 19/200 (9·5) 26·1 0·0 0·85 (0·64 to 1·11) 15 (–11 to 36)
Arinaitwe et al, 2014, Uganda Tororo ES 2011 0–1,2+ 29/227 (12·8) 25/325 (7·7) 97·3 0·2 0·78 (0·61 to 1·00) 22 (–0 to 39)
Coulibaly et al, 2014, Burkina Faso Ziniare CW 2011–12 0,1,2+ 32/155 (20·6) 106/757 (14·0) 75·3 0·0 0·74 (0·61 to 0·91) 26 (9 to 39)
Famanta et al, 2011, Mali Bamako CW 2009 0,1,2+ 16/102 (15·7) 25/257 (9·7) 15·2 0·0 0·85 (0·62 to 1·17) 15 (–17 to 38)
Desai et al, 2014, Kenya Nyanza ES 2011–12 0–1,2,3+ 10/135 (7·4) 59/734 (8·0) 93·0 5·7 0·99 (0·81 to 1·20) 1 (–20 to 19)
Feng et al, 2010, Malawi Blantyre ES 1997–99 0,1,2+ 49/215 (22·8) 84/697 (12·1) 63·6 0·0 0·68 (0·56 to 0·82) 32 (18 to 44)
Gutman et al, 2013, and 
Kalilani et al, 2014, Malawi
Southern Malawi ES 2009–11 0–1,2,3+ 28/334 (8·4) 103/1498 (6·9) 94·4 1·5 0·98 (0·83 to 1·14) 2 (–14 to 17)
Oduro et al, 2010, Ghana Navrongo CW 2006–07 0,1,2,3+ 76/391 (19·4) 342/1886 (18·1) 53·8 0·0 0·97 (0·89 to 1·05) 3 (–5 to 11)
Ndyomugyenyi et al, 2011, Uganda Kabale ES 2004–07 0,2+ 99/1577 (6·3) 107/1561 (6·9) 100·0 45·0 1·04 (0·92 to 1·19) –4 (–19 to 8)
Kayentao et al, 2014, Mali Kita CW 2009–10 0,1,2+ 18/124 (14·5) 38/420 (9·0) 15·2 0·0 0·74 (0·56 to 0·99) 26 (1 to 44)
van Eijk et al, 2004, Kenya Kisumu ES 1999–2000 0,1,2+ 112/948 (11·8) 70/925 (7·6) 42·8 0·0 0·74 (0·61 to 0·90) 26 (10 to 39)
Likwela et al, 2012, DR Congo Mikalayi CW 2007 0–1,2+ 35/363 (9·6) 2/114 (1·8) 76·9 0·0 0·43 (0·21 to 0·86) 57 (14 to 79)
Mace et al, 2014, Zambia Mansa ES 2009–10 0–1,2,3+ 17/157 (10·8) 13/266 (4·9) 83·7 0·0 0·71 (0·53 to 0·95) 29 (5 to 47)
Kilauzi et al, 2013, DR Congo Kinshasa CW 2011 0,1+ 21/204 (10·3) 32/501 (6·4) 100·0 8·1† 0·63 (0·38 to 1·05) 37 (–5 to 62)
Msyamboza et al, 2009, Malawi Chikwawa ES 2002–04 0–1,2,3+ 65/427 (15·2) 157/891 (17·6) 87·0 0·0 1·03 (0·92 to 1·15) –3 (–15 to 8)
Olorunda et al, 2013, Nigeria Ibadan CW 2010 0,1+ 22/246 (8·9) 4/84 (4·8) 92·4 2·5† 0·58 (0·24 to 1·41) 42 (–41 to 76)
Njagi et al, 2002, Kenya Bondo ES 1997–99 0,2+ 51/359 (14·2) 46/369 (12·5) 42·8 0·0 0·94 (0·78 to 1·13) 6 (–13 to 22)
Aziken et al, 2010, Nigeria Benin City CW 2009 0,1+ 61/371 (16·4) 14/370 (3·8) 84·2 47·4† 0·40 (0·28 to 0·56) 60 (44 to 72)
Kayentao et al, 2014, Mali San CW 2006 0,1,2+ 15/135 (11·1) 14/263 (5·3) 32·6 0·0 0·61 (0·37 to 0·99) 39 (1 to 63)
Tutu et al, 2011, Ghana Offinso CW 2005–07 0,1,2,3+ 62/499 (12·4) 250/2084 (12·0) 77·6 0·0 0·88 (0·80 to 0·96) 12 (4 to 20)
Gies et al, 2009, Burkina Faso Boromo CW 2004–06 0,1,2+ 19/52 (36·5) 204/1220 (16·7) 71·5 0·0 0·57 (0·48 to 0·68) 43 (32 to 52)
Cassam et al, 2007, Mozambique Gaza ES 2005–07 0,3+ 756/8650 (8·7) 488/6645 (7·3) 53·2 0·0 0·94 (0·91 to 0·98) 6 (2 to 9)
Tetteh-Ashong et al, 2005, Malawi Chikwawa ES 2005 0–1,2,3+ 6/42 (14·3) 13/186 (7·0) 94·1 0·0 0·74 (0·50 to 1·09) 26 (–9 to 50)
Mosha et al, 2014, Tanzania Rufiji, Moshi ES 2012 0–1,2+ 9/169 (5·3) 9/181 (5·0) 93·2 2·7 0·97 (0·62 to 1·52) 3 (–52 to 38)
Kayentao et al, 2014, Mali Koro CW 2006–07 0,1,2+ 13/130 (10·0) 14/221 (6·3) 44·8 0·0 0·69 (0·42 to 1·14) 31 (–14 to 58)
Ramharter et al, 2007, Gabon Lambarene CW 2005–06 0,1,2+ 11/97 (11·3) 60/596 (10·1) 57·9 0·0 0·82 (0·61 to 1·11) 18 (–11 to 39)
Tongo et al, 2011, Nigeria Ibadan CW 2007–08 0–1,2+ 68/649 (10·5) 4/147 (2·7) 92·4 2·5† 0·51 (0·31 to 0·84) 49 (16 to 69)
Parise et al, 1998, Kenya Kisumu ES 1994–96 0,2,3+ 52/340 (15·3) 53/656 (8·1) 42·8 0·0 0·80 (0·70 to 0·91) 20 (9 to 30)
Alli et al, 2013, Nigeria Kubwa CW 2010–11 0,1+ 4/158 (2·5) 0/42 (0·0) 84·2 47·4† 0·50 (0·05 to 4·78) 50 (–379 to 95)
Braun et al, 2015, Uganda Fort Portal ES 2013 0,1,2+ 8/56 (14·3) 52/552 (9·4) 100·0 12·9 0·79 (0·57 to 1·10) 21 (–10 to 43)
Hommerich et al, 2007, Ghana Agogo CW 2006 0,1,2,3+ 8/52 (15·4) 20/173 (11·6) 84·6 0·0 0·91 (0·66 to 1·25) 9 (–25 to 34)
Toure et al, 2014, Côte d’Ivoire Abidjan, Comoe CW 2009–10 0,1,2,3+ 50/436 (11·5) 61/876 (7·0) 52·1 0·9 0·80 (0·67 to 0·97) 20 (3 to 33)
Harrington et al, 2011, Tanzania Muheza ES 2002–05 0,1,2+ 6/80 (7·5) 11/292 (3·8) 100·0 13·0 0·57 (0·29 to 1·09) 43 (–9 to 71)
Suleiman et al, 2003, Sudan Wad Medani ES 1999–2001 0,2+ 19/53 (35·8) 2/57 (3·5) 13·3 0·0 0·31 (0·15 to 0·63) 69 (37 to 85)
Moleins et al, 2010, Senegal Oussouye CW 2007–08 0–1,2+ 6/55 (10·9) 6/96 (6·3) 43·0 0·0 0·76 (0·44 to 1·30) 24 (–30 to 56)
 Vanga-Bosson et al, 2011, Côte d’Ivoire National CW 2008 0,1,2,3+ 35/309 (11·3) 172/1636 (10·5) 52·1 0·9 0·88 (0·75 to 1·03) 12 (–3 to 25)
Mbaye et al, 2006, Gambia Farafenni CW 2002–04 0,2+ 46/716 (6·4) 40/738 (5·4) 46·8 0·0 0·94 (0·81 to 1·09) 6 (–9 to 19)
Ndeserua et al, 2015, Tanzania Rufiji ES 2012 0–1,2+ 12/166 (7·2) 10/184 (5·4) 75·0 0·0 0·87 (0·58 to 1·30) 13 (–30 to 42)
Kayentao et al, 2014, Mali San CW 2009–10 0,1,2+ 18/110 (16·4) 22/320 (6·9) 27·5 0·0 0·62 (0·43 to 0·87) 38 (13 to 57)
Likwela et al, 2012, DR Congo Kisangani ES 2007 0–1,2+ 16/50 (32·0) 6/87 (6·9) 74·1 5·6† 0·46 (0·30 to 0·72) 54 (28 to 70)
Feng et al, 2010, Malawi Blantyre ES 1999–2001 0,1,2+ 20/117 (17·1) 85/719 (11·8) 80·3 0·0 0·77 (0·60 to 0·99) 23 (1 to 40)
Tonga et al, 2013, Cameroon Sanaga–Maritime CW 2011–12 0,1,2+ 7/68 (10·3) 6/127 (4·7) 76·5 5·9† 0·62 (0·32 to 1·19) 38 (–19 to 68)
Bouyou-Akotet et al, 2016, Gabon Libreville, Melen CW 2011 0,1,2+ 5/58 (8·6) 14/241 (5·8) 66·7 0·0 0·82 (0·50 to 1·36) 18 (–36 to 50)
Feng et al, 2010, Malawi Blantyre ES 2002–06 0,1,2,3+ 29/234 (12·4) 212/2137 (9·9) 93·5 2·0 0·89 (0·79 to 1·00) 11 (0 to 21)
Sirima et al, 2006, Burkina Faso Koupela CW 2004 0,1,2,3+ 16/66 (24·2) 119/1054 (11·3) 48·1 0·0 0·68 (0·58 to 0·79) 32 (21 to 42)
Falade et al, 2007, Nigeria Ibadan CW 2003–04 0,1+ 16/171 (9·4) 31/595 (5·2) 63·0 0·0 0·73 (0·53 to 1·00) 27 (0 to 47)
Igboeli et al, 2017, Nigeria Enugu State CW 2013 0,1+ 8/101 (7·9) 7/315 (2·2) 96·8 52·6† 0·56 (0·36 to 0·88) 44 (12 to 64)
Kayentao et al, 2014, Mali Djenne CW 2006 0,1,2+ 10/110 (9·1) 13/245 (5·3) 32·7 0·0 0·74 (0·46 to 1·17) 26 (–17 to 54)
Kayentao et al, 2014, Mali Bougouni CW 2006–07 0,1,2+ 11/101 (10·9) 17/306 (5·6) 33·8 0·0 0·70 (0·44 to 1·09) 30 (–9 to 56)
Muhammad et al, 2016, Nigeria Nguru, Yobe CW 2014 0–1,2+ 58/104 (55·8) 10/80 (12·5) 24·5 0·0 0·47 (0·35 to 0·64) 53 (36 to 65)
Likwela et al, 2012, DR Congo Rutsuhuru ES 2007 0–1,2+ 16/177 (9·0) 39/493 (7·9) 88·1 45·6 0·94 (0·71 to 1·24) 6 (–24 to 29)
D+L subtotal  (I2 31·4%, p=0·15) 0·93 (0·87 to 1·00) 7 (0 to 13)
D+L subtotal  (I2 70·5%, p<0·0001) 0·73 (0·67 to 0·79) 27 (21 to 33)
D+L subtotal  (I2 66·7%, p=0·0001) 0·79 (0·72 to 0·87) 21 (14 to 29) 
D+L overall  (I2 69·5%, p<0·0001) 0·79 (0·75 to 0·83) 21 (17 to 25)
Reference Comparison
Site Region Study
period
Sulfadoxine-
pyrimethamine
dose category
Low birthweight
prevalence, n/N (%)*
Ala437Gly Ala581GlyLys540Glu
Mutation prevalence, % Low birthweight
relative risk
reduction per 
dose, % (95% CI)
Risk ratio
trend (95% CI)
Study 
weight,
% (D+L)
IPTp better IPTp worse
10·2 0·5 2
2·14
2·44
2·54
1·04
1·14
1·15
1·83
2·02
2·42
1·58
2·44
2·46
2·78
3·36
2·98
1·77
2·43
0·49
1·74
0·85
3·14
0·33
2·52
1·39
0·89
3·28
2·63
3·59
1·24
1·01
0·85
1·69
0·87
2·98
0·05
1·49
1·57
2·52
0·55
0·49
0·76
2·78
2·81
1·16
1·41
1·06
1·99
0·55
0·85
3·11
2·78
1·60
1·01
0·96
1·01
1·67
1·82
22·71
48·32
28·97
100·00
0·0
68·6
72·7
87·5
95·1
6·9
25·4
97·5
0·0
0·7
95·6
74·0
99·6
0·0
100·0
0·7
31·1
11·3
84·0
18·9
92·7
1·0
31·1
0·0
0·0
0·0
0·2
47·6
94·8
88·3
0·1
3·3
1·0
31·1
0·0
100·0
1·4
0·9
90·2
0·0
0·1
0·9
0·0
76·3
0·0
27·8
84·0
0·0
0·0
94·7
0·1
0·0
0·0
0·0
0·2
0·0
91·2
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prevalence of this quintuple mutant was more than 50%, 
the prevalence of the dhps Ala581Gly mutation served as 
a proxy for the sextuple mutant. Two areas were identified 
where the sextuple mutant was more than 10%: 
northeastern Tanzania, and the area crossing the borders 
of southwestern Uganda, eastern Rwanda, eastern 
Democratic Republic of the Congo, and northwestern 
Tanzania (appendix p 4). The prevalence of each point 
mutation and the P falciparum parasite prevalence in 
children aged 2–10 years (PfPR2–10; using data from the 
Malaria Atlas Project) was matched to each study by time 
(the same year for PfPR2–10 and within 2 years before or 
after for point mutations) and by location using latitude 
and longitude (within 300 km where possible).24 For 
national surveys, these prevalence data were calculated 
for the administrative boundary of the given survey using 
Malaria Atlas Project data and WWARN’s geospatial 
models (appendix p 4).22 
Definition of resistance categories
To stratify resistance into low, moderate, and high 
levels, different combinations of threshold levels (at 5% 
step increases) of the resistance-associated mutations 
in dhps were explored in the aggregated-data meta-
analysis. Because of distinct parasite populations and 
distributions of mutations in each region,25 threshold 
analysis was done separately for central and west Africa 
and for east and southern Africa. Results were then 
combined to obtain a single categorical variable that 
represented the optimal thresholds based on the R² for 
each region.
Statistical analysis
The primary outcome was low birthweight. Secondary 
outcomes included anaemia, malaria, preterm delivery, 
birthweight, haemoglobin level, and gestational age. 
Analyses of clinical studies were done with Stata 
(version 14). A two-stage random-effects meta-analysis 
was done by use of a generalised least-squares regression 
for trend estimation of summarised dose-response 
data.26,27 Effect sizes were expressed as relative risk 
reduction (RRR; 100 × [1 – relative risk]) for trend (appendix 
p 4), and were then combined across studies with use 
of a random-effects meta-analysis, with heterogeneity 
quantified using the I² statistic. Potential modifying 
effects of sulfadoxine-pyrimethamine resistance were 
examined with multi variate linear meta-regression, 
adjusting for the following prespecified covariates: 
malaria transmission, study quality, average number of 
sulfa doxine-pyrimethamine doses, and proportion of 
paucigravidae (defined as women in their first or second 
pregnancy).28 The proportion of women using insecticide-
treated nets was not found to be associated with resistance 
level in our analyses and was not included as covariate in 
the metaregression. Subgroup analyses by gravidity 
(paucigravidae vs multi gravidae) were also done. For the 
assessment of the effect of sulfadoxine-pyrimethamine 
IPTp on continuous outcomes, only the no doses group 
versus the two or more doses group were compared. 
Further sensitivity analysis was done by excluding low-
quality studies and exploring the presence and impact of 
potential small-study effects due to publication and other 
biases (appendix p 4).29
n Univariate meta-regression Multivariate meta-regression*
Coefficient (95% CI) p value τ² I², % R², % Coefficient (95% CI) p value τ² I², % R², %
dhps Ala437Gly prevalence†
All studies 57 1·001 (0·999–1·004) 0·35 0·02596 69·9 1·8 1·001 (0·999–1·004) 0·25 0·01645 57·7 37·8
Excluding low-quality studies‡ 50 1·002 (0·999–1·004) 0·13 0·02079 67·3 7·5 1·002 (1·000–1·004) 0·08 0·01323 54·1 41·1
Restricted to largest 50% of 
studies§
29 1·003 (1·000–1·005) 0·06 0·01615 73·9 13·3 1·002 (1·000–1·005) 0·09 0·01137 62·1 39·0
dhps Lys540Glu prevalence†
All studies 57 1·002 (1·001–1·003) 0·0060 0·02142 66·2 19·0 1·002 (1·001–1·003) 0·0031 0·01222 53·7 53·8
Excluding low-quality studies‡ 50 1·002 (1·000–1·003) 0·0090 0·01732 61·9 22·9 1·002 (1·000–1·003) 0·0160 0·01133 51·1 49·6
Restricted to largest 50% of 
studies§
29 1·002 (1·000–1·003) 0·0223 0·01469 70·5 21·1 1·002 (1·000–1·003) 0·0132 0·00909 58·7 51·2
Resistance strata¶
All studies 57 1·10 (1·03–1·18) 0·0054 0·02040 65·4 22·8 1·10 (1·03–1·17) 0·0043 0·01184 52·9 55·2
Excluding low-quality studies‡ 50 1·10 (1·03–1·18) 0·0075 0·01687 61·6 24·9 1·09 (1·02–1·16) 0·0095 0·01067 49·7 52·5
Restricted to largest 50% of 
studies§
29 1·10 (1·02–1·18) 0·0122 0·01386 69·7 25·6 1·10 (1·03–1·17) 0·0067 0·00802 55·9 56·9
dhps=Plasmodium falciparum dihydropteroate synthase. *Adjusted for malaria transmission intensity, average number of sulfadoxine-pyrimethamine doses, study quality, and 
proportion of paucigravidae in study. †In the meta-regression, the sulfadoxine-pyrimethamine resistance variable was introduced as a linear continuous variable reflecting 1% 
stepped increases in prevalence of the resistance marker. ‡Excludes studies with less than three of six stars for quality. §To ascertain the effect of potential bias due to small-study 
effect, the analysis was restricted to the largest 50% of studies, based on their standard error of the log relative risk for low birthweight. ¶Sulfadoxine-pyrimethamine resistance, 
defined by the prevalence of molecular markers, stratified into low (dhps Ala437Gly <90% in central and west Africa or dhps Lys540Glu <30% in east and southern Africa), moderate 
(dhps Ala437Gly ≥90% in central and west Africa, or dhps Lys540Glu ≥30% and <90% in east and southern Africa), and high (dhps Lys540Glu ≥90% in east and southern Africa).
Table: Effect of sulfadoxine-pyrimethamine resistance on the effectiveness of sulfadoxine-pyrimethamine IPTp to prevent low birthweight in women 
receiving intermittent preventive treatment during pregnancy (sub-Saharan Africa, 1997–2013, aggregated data)
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The survey analysis was done in R and restricted to the 
higher-resistance areas with more than 80% prevalence 
of dhps Lys540Glu. Only the most recent livebirth within 
the past 2 years was considered. To mitigate potential 
confounding of the effect of sulfadoxine-pyrimethamine 
dose on birthweight, exact matching was used (appendix 
p 4).4 The modifying effect of sulfadoxine-pyrimethamine 
resistance was first assessed for each survey by use of 
random-effects log-binomial regression models for low 
birthweight and linear regression for birthweight with 
the matched birth strata included as a random intercept 
using the lme4 package in R.30 IPTp exposures were 
considered as continuous variables similar to the 
aggregated meta-analysis. The effect measures were 
then further evaluated by resistance strata (quintiles) 
and compared by use of meta-regression.
This study is registered with PROSPERO, number 
42016035540.
Role of the funding source
Except for the US Centers for Disease Control and 
Prevention (CDC) and WWARN, the funders of the study 
had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. CDC and 
WWARN staff participated in the conduct of the study. 
AMvE, FOtK and DAL had full access to all the data in 
the study. AMvE and FOtK had final responsibility for the 
decision to submit for publication.
Results
For the aggregated-data meta-analysis, we identified 
2021 records through database searching. After removal of 
duplicates, 1097 articles were assessed for eligibility, of 
which 66 were included in the review: 58 observational 
studies and eight trials (figure 1). A summary of the 
included studies is provided in the appendix (p 6). Of these, 
50 source articles from 17 countries (appendix p 30) were 
included in the analysis of low birthweight, involving 
57 datapoints (henceforth referred to as studies) and 
59 457 births. The remaining 16 studies did not provide data 
on low birthweight, but contributed to the analysis 
of secondary outcomes. In central and west Africa 
(31 studies), the median prevalence of dhps Ala437Gly was 
57·9% (IQR 39·3–77·6; range 15·2–100·0), despite a low 
prevalence of dhps Lys540Glu (0·1% [IQR 0·0–0·9; 
range 0·0–18·9]), whereas, in east and southern Africa 
(26 studies), the prevalence of dhps Ala437Gly (85·4% 
[IQR 62·9–94·1; range 13·3–100·0]) was similar to that of 
dhps Lys540Glu (85·8% [IQR 47·6–94·8; range 0·0–100·0]; 
appendix pp 27, 31). The dhps Ala581Gly mutation (used as 
a proxy for the sextuple mutant) mainly occurred in areas 
with a dhps Lys540Glu prevalence of more than 80% 
in east and southern Africa (figure 2, appendix p 27). 
Among sulfadoxine-pyrimethamine recipients, the median 
number of sulfadoxine-pyrimethamine doses received 
(study-level) was 1·7 (IQR 1·3–2·4; appendix p 13). The 
number of sulfadoxine-pyrimethamine doses received by 
study participants was not correlated with the prevalence of 
dhps Ala437Gly (r=–0·0295, p=0·83) or dhps Lys540Glu 
(r=0·1594, p=0·24).
Overall, per dose of sulfadoxine-pyrimethamine, 
sulfadoxine-pyrimethamine IPTp was associated with an 
RRR for low birthweight of 21% (95% CI 17–25; 57 studies; 
figure 2). RRR was 22% (17–27; 34 studies) in paucigravidae 
and 18% (11–24; 31 studies) in multigravidae (appendix 
p 17). There was substantial heterogeneity between studies 
(I²=69·5%, p<0·0001; figure 2).
Univariate and multivariate meta-regression analyses 
showed a linear trend towards decreasing effectiveness 
of sulfadoxine-pyrimethamine IPTp (as indicated by the 
log relative risk of low birthweight moving closer to the 
null) with increasing prevalence of dhps Lys540Glu (table, 
figure 3). No differences were seen by gravidity (appendix 
Figure 3: Correlation between relative risk for low birthweight in women 
receiving IPTp and the prevalence of dhps Ala437Gly or dhps Lys540Glu 
mutations in 57 studies
Meta-regression bubble plots show the log of the relative risk estimates for low 
birthweight across each sulfadoxine-pyrimethamine dose category, obtained by 
use of generalised least-squares regression for trend estimation of summarised 
dose-response data, with 95% CI of the regression line represented by the 
shaded area. The size of the bubbles for individual studies is proportional to the 
random effects study weights. A positive slope indicates decreasing 
effectiveness of sulfadoxine-pyrimethamine IPTp for averting low birthweight 
with increasing mutation prevalence. dhps=dihydropteroate synthase. 
IPTp=intermittent preventive treatment in pregnancy.
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p 16). No significant trend was observed for dhps 
Ala437Gly (table, figure 3). Of the different thresholds 
used to stratify resistance into low, medium, and high, 
the most predictive combination was low resistance 
defined as dhps Ala437Gly less than 90% in central 
and west Africa or dhps Lys540Glu less than 30% in 
east and southern Africa (RRR 27% [95% CI 21–33]); 
moderate resistance defined as dhps Ala437Gly 90% or 
higher (central and west Africa) or dhps Lys540Glu 30% 
or higher and less than 90% in east and southern Africa 
(RRR 21% [14–29]); and high resistance defined as dhps 
Lys540Glu 90% or higher in east and southern Africa 
(RRR 7% [0–13]; p=0·0054 for linear trend; table). These 
definitions of resistance strata explained 22·8% of the 
between-study variance (R²) in univariate models and, 
combined with other covariates, 55·2% in multivariate 
models (table). Very similar results were obtained if 
alternative thresholds (<20% or <40%) for dhps Lys540Glu 
prevalence were used to define low resistance, or if a dhps 
Ala437Gly prevalence of less than 80% was used to define 
low resistance, or if the presence (≥1%) of dhps Ala581Gly 
(instead of dhps Lys540Glu ≥90%) was used to define 
high resistance (appendix p 18).
Meta-regression results were similar after the exclusion 
of low-quality studies (table). There was evidence for 
significant small-study effects (p<0·0001), but this effect 
was observed in all three resistance strata (appendix p 32), 
and restricting the analysis to the larger 50% of studies 
did not change the observed trend towards decreasing 
efficacy with increasing resistance (table). By 
region, multivariate meta-regression showed significant 
correlations between low birthweight and dhps Ala437Gly 
prevalence, dhps Lys540Glu prevalence, and resistance 
strata only in east and southern Africa (appendix p 16).
Only five studies were done in areas that had a more 
than 10% prevalence of sextuple-mutant P falciparum 
parasites (pooled dhps Ala581Gly prevalence 32% [95% CI 
17 to 48]). Substantial heterogeneity in effect size was 
found among these studies (I²=68·8%, p=0·012; 
appendix p 33): the three studies with a small sample size 
in the reference group had an RRR of 35% (14 to 51; 
pooled dhps Ala581Gly prevalence 21%), whereas the two 
remaining larger studies, both conducted in areas with 
the highest dhps Ala581Gly prevalence (pooled prevalence 
46%) had an RRR of –2% (–15 to 9; p=0·0518 for subgroup 
difference).
When outcomes other than low birthweight were 
considered, we observed a linear trend towards decreasing 
effectiveness of IPTp with increasing prevalence of dhps 
Lys540Glu for maternal moderate-to-severe anaemia 
and for malaria infection (maternal, placental, or any 
malaria) at delivery. The RRRs at delivery for moderate-to-
severe anaemia were 41% (28 to 51) in low-resistance, 
20% (1 to 35) in moderate-resistance, and 13% (3 to 22) 
in high-resistance areas (ptrend=0·0049); and for any 
malaria infection were 20% (13 to 26) in low-resistance, 
18% (10 to 26) in moderate-resistance, and 3% (–3 to 9) in 
high-resistance areas (ptrend=0·0164; appendix pp 21–26).
The analysis of individual participant data from surveys 
focused on areas with a more than 80% prevalence of the 
dhps Lys540Glu mutation, with the aim of ascertaining 
the effect of the sextuple-mutant P falciparum parasite in 
areas previously defined as super resistant (>10% dhps 
Ala581Gly prevalence).16 Of 138 publicly available surveys, 
39 met the inclusion criteria, and 13 surveys that included 
data from areas with a dhps Lys540Glu prevalence of 
more than 80% or with super resistance (all in east and 
southern Africa from 2008–15, and comprising 
Figure 4: Relative risk for low birthweight associated with number of sulfadoxine-pyrimethamine IPTp doses by resistance strata in areas with super resistance or dhps Lys540Glu of more 
than 80% in east and southern Africa
(A) Linear meta-regression bubble plot with solid line representing the regression line and shaded area representing the 95% CI. (B) Forest plot. Individual observations in all areas with a dhps 
Lys540Glu prevalence of more than 80% were divided into quintiles after excluding the surveys in the super-resistant areas. Super-resistant areas were defined as those with a dhps Ala581Gly 
prevalence of more than 10% (southwestern Uganda, northern Tanzania, and eastern Democratic Republic of the Congo).16 Overall, sulfadoxine-pyrimethamine IPTp was associated with an RRR of 
11% (95% CI 8–13) for low birthweight. The RRR was 10% (7–12) in areas with a dhps Lys540Glu prevalence of more than 90% and Ala581Gly prevalence of less than 10%. dhps=dihydropteroate 
synthase. IPTp=intermittent preventive treatment in pregnancy. RRR=relative risk reduction. *Number of surveys (total 13) that contributed to each quintile group; surveys could contribute to 
more than one group. 
Mean dhps
Lys540Glu
prevalence,
% (range)
First quintile
Second quintile
Third quintile
Fourth quintile
Fifth quintile
Super resistant
Random effects model
85·5 (80·2–89·7)
91·9 (89·7–93·1)
94·0 (93·1–94·6)
95·3 (94·6–95·8)
97·0 (95·8–98·5)
83·7 (70·7–96·3)
694/3958 (17·5) 
766/3923 (19·5) 
446/2438 (18·3) 
519/2552 (20·3) 
589/2850 (20·7) 
86/891 (9·7)
217/2000 (10·9) 
202/1872 (10·8) 
347/2445 (14·2) 
322/2452 (13·1) 
248/1891 (13·1) 
73/815 (9·0)
152/1520 (10·0) 
160/1522 (10·5) 
239/2096 (11·4) 
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42 394 singleton livebirths) were included in the analysis 
after exact matching of probability of receiving IPTp, 
resistance, and malaria transmission intensity data 
(figure 1). Sulfadoxine-pyrimethamine IPTp in these 
areas was associated with an RRR of 11% (95% CI 8 to 13) 
for low birthweight. Even in areas with a dhps Lys540Glu 
prevalence of more than 90% and a dhps Ala581Gly 
prevalence of up to 10%, sulfadoxine-pyrimethamine 
IPTp was associated with significantly reduced risk of 
low birthweight (RRR 10% [7 to 12]; figure 4). However, in 
the two super-resistant areas, sulfadoxine-pyrimethamine 
IPTp did not protect against low birthweight (RRR 0·5% 
[–16 to 14]; figure 4). In these two areas, the pooled 
prevalence of the dhps Ala581Gly mutation across all 
contemporary molecular studies was 37% (29 to 46; 
appendix p 34).
Discussion
In our meta-analysis of aggregated data from 57 clinical 
studies, increases in the prevalence of two molecular 
markers of sulfadoxine resistance were associated with 
clear reductions in the effectiveness of sulfadoxine-
pyrimethamine IPTp to avert low birthweight and other 
outcomes such as malaria infection at delivery and 
maternal anaemia. In our parallel analysis of individual 
participant data from nationally representative surveys, 
sulfadoxine-pyrimethamine IPTp was associated with a 
significant but modest protective effect against low 
birthweight in areas where the P falciparum dhps Lys540Glu 
mutation prevalence was 90% or higher and the prevalence 
of sextuple-mutant parasites was less than 10%.16 However, 
these surveys also showed that, in areas where sextuple-
mutant parasites are common (pooled prevalence estimate 
37%), sulfadoxine-pyrimethamine IPTp did not protect 
against low birthweight. These findings are consistent 
with our understanding of the incremental increase in 
resistance to sulfadoxine-pyrimethamine with successive 
mutations in the dhfr and dhps genes, and with the previous 
studies that showed compromised efficacy of sulfadoxine-
pyrimethamine in women infected with sextuple-mutant 
P falciparum.12–15 This high resistance is currently restricted 
to a few foci in east Africa,16 but its spread would 
have important implications for the continued use of 
sulfadoxine-pyrimethamine for IPTp.
Compared with other markers of sulfadoxine-
pyrimethamine resistance, fewer data are available on 
the distribution of the dhps Ala581Gly mutation. There-
fore, the aggregated-data meta-analysis was limited in 
its ability to define and validate different thresholds for 
the dhps Ala581Gly mutation. There were only 
five studies done in areas in east and southern Africa 
with a dhps Ala581Gly prevalence of more than 10%, and 
none were done in areas with a dhps Ala581Gly 
prevalence between 13% and 43%. Within these studies, 
there was also substantial between-study heterogeneity 
in the effect of treatment on low birthweight: the 
three smaller studies, with only four to eight low 
birthweight events in the reference groups,12,15,31 showed 
a pooled effect size of 35% (95% CI 14 to 51), whereas 
the studies with larger reference groups reported an 
effect size of –2% (–15 to 9; appendix p 33).32,33 The 
results of these larger two studies, which were done in 
areas with a dhps Ala581Gly prevalence of more than 
45%, are consistent with the lack of effect on low 
birthweight in our analysis of survey data, which was 
based on much larger sample sizes and areas with an 
average dhps Ala581Gly prevalence of 37%.
Irrespective of sulfadoxine-pyrimethamine resistance, 
we observed large between-study heterogeneity in the 
treatment effect on low birthweight among the 57 clinical 
studies. This can be explained, in part, by the multicausal 
nature of low birthweight and the varying population-
attributable fractions of malaria towards low birthweight, 
which depend on transmission intensity and uptake of 
interventions such as insecticide-treated nets. In the 
current study, insecticide-treated net use was not an 
effect modifier or confounder, but malaria transmission 
intensity was correlated with resistance (lower trans-
mission levels were associated with higher resistance 
levels) and was thus a potential confounder, which is 
why it was important to adjust for malaria transmission 
in our models. Nevertheless, estimates of the effect of 
sulfadoxine-pyrimethamine resistance on the 
effectiveness of sulfadoxine-pyrimethamine IPTp for 
averting low birthweight (ie, the slope of the meta-
regression lines) were largely unaffected by the inclusion 
of four co variates—malaria transmission, study quality, 
mean number of sulfadoxine-pyrimethamine doses, and 
pro portion of paucigravidae—in the models, suggesting 
minimal confounding by these variables overall.
Although the effectiveness of IPTp for low birthweight 
decreased with increasing resistance, sulfadoxine-
pyrimethamine IPTp remained associated with a 7–10% 
reduced risk of low birthweight even in areas where the 
resistant quintuple-mutant haplotype is fixed. This small 
but resilient effect on low birthweight contrasts with the 
lack of effect (RRR 3%) on malaria infection in high-
resistance areas seen in the aggregated-data meta-analysis 
(appendix p 19), and with the previously observed 
unfavourable parasitological response in asymptomatic 
pregnant women receiving sulfadoxine-pyrimethamine 
IPTp in these areas, where clearance of parasites by day 42 
was achieved in only 50% of paucigravidae.7 That IPTp can 
decrease risk of low birthweight even in areas where its 
efficacy for clearance of infection is compromised might 
suggest that suppression, rather than radical clearance of 
parasites, is required to mitigate the adverse effects of 
malaria on placental function and growth, as observed in 
multigravidae (who acquire protective antimalarial 
immunity over successive pregnancies). Alternatively, 
sulfadoxine-pyrimethamine might have beneficial effects 
on birthweight that are independent of its antimalarial 
properties and are, therefore, unaffected by parasite 
resistance (eg, anti microbial effects,32–34 or effects related to 
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immuno modulation, similar to those described for co-
trimoxazole35).
The differences in P falciparum parasite populations 
(shown in the scatter plot of the prevalence of dhps 
Ala437Gly and Lys540Glu mutations in the appendix 
p  31) reflect the distinct geographical origins of two or 
three parasite populations in east and west Africa.25 In 
east and southern Africa, the combination of the 
resistance alleles at dhps codons 540 and 581 could 
be  considered to track sulfadoxine-pyrimethamine 
resistance. In central and west Africa, where the dhps 
Lys540Glu mutation is absent or rare, tracking dhps 
Ala437Gly might be informative. However, other 
mutations have started to emerge in west Africa, such as 
dhps Ile431Val, which has been reported on a haplotype 
bearing mutant alleles at codons 581 and 613 but a wild-
type allele at codon 540.36,37 The clinical implications of 
such new haplotypes require further study.
Our analyses have important limitations. First, the 
potential biases associated with observational data, in 
which the number of sulfadoxine-pyrimethamine doses 
is not determined by the study, have been discussed in 
detail elsewhere.4 Although the use of exact matching 
and multivariate models will have reduced the potential 
for bias in the surveys, residual confounding cannot 
be excluded. Second, national surveys are subject 
to measure ment error and information bias from 
respondent recall and self-report.4 Similar limitations 
apply to the aggregated-data analysis, which could only 
adjust for study-level covariates. For some studies, 
time-matched local resistance data were not available 
and were obtained from other sources, which are less 
precise. Some studies were considered to be of poor 
quality, with a trend towards greater effectiveness with 
decreasing study quality, but sensitivity analysis showed 
that these low-quality studies were equally distributed 
across the resistance spectrum and did not affect the 
conclusions. Similarly, there was evidence of a small-
study effect, but this effect was also observed in all 
three resistance strata, and restricting the analysis to 
the largest 50% of studies (which are least likely to 
be affected by publication bias) did not alter the 
conclusions. In addition, the meta-analysis suffered 
from design and reporting variation and small numbers 
in the extreme dose groups (zero doses and three or 
more doses). This limitation was partly mitigated by 
use of a dose-response analysis that placed less 
emphasis on the extreme dose groups.
This is the most comprehensive study of the effect of 
sulfadoxine-pyrimethamine resistance on the effective-
ness of sulfadoxine-pyrimethamine IPTp, involving 
57 clinical studies, 13 nationally representative surveys, 
and more than 100 000 births. The data show that, despite 
the substantial heterogeneity between studies with regard 
to the effectiveness of sulfadoxine-pyrimethamine IPTp 
on low birthweight, increasing prevalence of molecular 
markers of sulfadoxine resistance is correlated with a 
decrease in effectiveness of sulfadoxine-pyrimethamine 
to prevent low birth weight and malaria infections. These 
findings suggest that molecular monitoring of 
sulfadoxine-pyrimethamine resistance is a potential 
policy tool to guide the use of sulfadoxine-pyrimethamine 
IPTp. It is reassuring that a protective association of 
sulfadoxine-pyrimethamine IPTp with low birthweight 
can be detected even in high-resistance areas where 
quintuple-mutant P falciparum parasites are almost fixed. 
However, sulfadoxine-pyrimethamine IPTp is not likely to 
reduce malaria and malaria-associated low birthweight in 
areas where the prevalence of sextuple-mutant parasites, 
with the dhps Ala581Gly mutation, exceed 37% (the pooled 
estimate in the high-resistance areas). For these areas, the 
search for alternative strategies or drugs to replace 
sulfadoxine-pyrimethamine IPTp is a pressing research 
priority for the control of malaria in pregnancy.
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